The announcement of the exclusive supply agreement indicates a significant expansion for Avicanna into the European market, which is a positive development. However, the immediate reaction in the stock price was negative, likely due to market dynamics or investor expectations. The short-term impact is negative as evidenced by the decrease in share price, but this could be a reaction to broader market conditions or the lack of details about the pharmaceutical partner.